146 related articles for article (PubMed ID: 2056773)
1. Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid.
Wiernik PH; Dutcher JP; Paietta E; Hittelman WN; Vyas R; Strack M; Castaigne S; Degos L; Gallagher RE
Leukemia; 1991 Jun; 5(6):504-9. PubMed ID: 2056773
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all-trans-retinoic acid].
Tsurugano S; Togawa A; Soda Y; Miwa A; Takaku F; Yuo A; Yamada K; Hirai H
Rinsho Ketsueki; 1994 Jan; 35(1):36-41. PubMed ID: 8139100
[TBL] [Abstract][Full Text] [Related]
3. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
5. [Extramedullary blast crisis of mixed precursor T lymphoblastic and myeloblastic features in a patient with chronic myelogenous leukemia successfully treated with low-dose oral etoposide].
Konaka Y; Namiuchi S
Rinsho Ketsueki; 1993 Dec; 34(12):1556-61. PubMed ID: 8295329
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease.
Notario A; Rolandi ML; Mazzucchelli I
Haematologica; 1996; 81(3):261-4. PubMed ID: 8767533
[TBL] [Abstract][Full Text] [Related]
7. [Blast differentiation in a patient with chronic myeloid leukemia in blast crisis using retinoic acid].
Burgaleta C; Villalba S; Ferro MT
Sangre (Barc); 1995 Dec; 40(6):509-12. PubMed ID: 8850236
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Higashi T; Tsukada J; Kato C; Iwashige A; Mizobe T; Machida S; Morimoto H; Ogawa R; Toda Y; Tanaka Y
Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
[TBL] [Abstract][Full Text] [Related]
9. A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.
Naeem M; Harrison K; Barton K; Nand S; Alkan S
Eur J Haematol; 2006 Feb; 76(2):164-6. PubMed ID: 16405439
[TBL] [Abstract][Full Text] [Related]
10. [Retinoic acid and 12-0-tetradecanoylphorbol-13-acetate (TPA) inducing bipotent differentiation of cultured primary bone marrow cells from leukemia patients].
Chen ZX; Wu WL
Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):26-9. PubMed ID: 1889336
[TBL] [Abstract][Full Text] [Related]
11. Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common?
Brodsky RA; Jones RJ
Leukemia; 2004 Oct; 18(10):1740-2. PubMed ID: 15356647
[TBL] [Abstract][Full Text] [Related]
12. Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia.
Wujcik D
Oncol Nurs Forum; 1996 Apr; 23(3):478-87. PubMed ID: 8801508
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin in blastic crisis of chronic myelogenous leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
15. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
16. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
17. Heterogenous response of primary cultured bone marrow cells of patients with different varieties of leukemia to differentiation inducers.
Chen ZX; Wang W; Wu WL
Chin Med J (Engl); 1989 Mar; 102(3):174-82. PubMed ID: 2503303
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
19. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.
Gotoh A; Miyazawa K; Uchida Y; Sashida G; Kawakubo K; Kuriyama Y; Ohyashiki K
Int J Hematol; 2002 Feb; 75(2):191-4. PubMed ID: 11939268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
